Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?

Simple item page
dc.contributor.authorJames P. C. Coverdale
dc.contributor.authorThaisa Laroiya-McCarron
dc.contributor.authorIsolda Romero-Canelón
dc.date.accessioned2024-08-15T14:03:41Z
dc.date.available2024-08-15T14:03:41Z
dc.identifier.urihttps://tustorage.ulb.tu-darmstadt.de/handle/tustorage/7100
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.ddc540
dc.titleDesigning Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
dc.typesupplierxml
dspace.entity.typeDistribution
relation.isDatasetOfDistribution640a2249-f583-4c20-9583-034b81bf0f6e
relation.isDatasetOfDistribution.latestForDiscovery640a2249-f583-4c20-9583-034b81bf0f6e

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
inorganics-07-03-00031.xml
Size:
187.09 KB
Format:
Extensible Markup Language
Download

Collections

2019